Jiro Minami

TL;DR: Results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM.

TL;DR: The results indicate thatHDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM, which significantly enhances bortezomib-induced cytotoxicity.

TL;DR: The data show that PBS-1086 is a promising dual inhibitor of the canonical and noncanonical NF-κB pathways, and this preclinical study provides the framework for clinical evaluation of PBS- 1086 in combination with bortezomib for the treatment of multiple myeloma and related bone lesions.

TL;DR: Examination of the biologic impact of selective and potent Akt inhibition by a novel allosteric inhibitor TAS-117 shows that it triggers anti-MM activities in vitro and in vivo, as well as enhances cytotoxicity of proteasome inhibition, providing the preclinical framework for clinical evaluation of selective Akt inhibitors, alone and in combination with prote asome inhibitors in MM.

TL;DR: Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma